Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin–bleomycin–vinblastine–dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study / Giordano, C., Picardi, M., Pugliese, N., Vincenzi, A., Avilia, S., De Fazio, L., Lamagna, M., Reina, R., Scarpa, A., Lombardi, A., Vigliar, E., Troncone, G., Mascolo, M., Mainolfi, C., Fonti, R., Del Vecchio, S., Damiano, V., Bianco, R., Trastulli, F., Annunziata, M., et al.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 1365-2141. - 206:5(2025), pp. 1502-1507. [10.1111/bjh.20053]
Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin–bleomycin–vinblastine–dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study
Giordano C.
Primo
Formal Analysis
;Pugliese N.;Vincenzi A.;De Fazio L.;Reina R.;Vigliar E.;Mainolfi C.;Fonti R.;Del Vecchio S.;Damiano V.;Trastulli F.;Carchia M.;
2025
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
